Published in Bone on April 01, 2004
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res (2010) 2.39
A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res (2010) 2.32
Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res (2012) 2.05
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Chronic kidney disease and bone fracture: a growing concern. Kidney Int (2008) 1.76
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone (2009) 1.47
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int (2009) 1.44
Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab (2012) 1.27
Tibial geometry is associated with failure load ex vivo: a MRI, pQCT and DXA study. Osteoporos Int (2007) 1.26
An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol (2006) 1.20
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med (2012) 1.17
Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res (2008) 1.16
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
A biomechanical analysis of the effects of resorption cavities on cancellous bone strength. J Bone Miner Res (2006) 1.11
Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int (2007) 1.10
Role of trabecular microarchitecture in whole-vertebral body biomechanical behavior. J Bone Miner Res (2009) 1.08
Variations in morphological and biomechanical indices at the distal radius in subjects with identical BMD. J Biomech (2010) 1.03
Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int (2007) 1.03
Microstructure and nanomechanical properties in osteons relate to tissue and animal age. J Biomech (2010) 1.03
Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int (2006) 1.02
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Proximal femur mechanical adaptation to weight gain in late adolescence: a six-year longitudinal study. J Bone Miner Res (2008) 0.96
Effects of genistein on vertebral trabecular bone microstructure, bone mineral density, microcracks, osteocyte density, and bone strength in ovariectomized rats. J Bone Miner Metab (2008) 0.94
Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int (2012) 0.94
Automated simulation of areal bone mineral density assessment in the distal radius from high-resolution peripheral quantitative computed tomography. Osteoporos Int (2009) 0.93
Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int (2011) 0.93
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res (2008) 0.92
Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporos Int (2006) 0.91
The relationships among total body fat, bone mineral content and bone marrow adipose tissue in early-pubertal girls. Bonekey Rep (2013) 0.90
Teriparatide in the management of osteoporosis. Clin Interv Aging (2007) 0.89
Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect. J Med Food (2012) 0.88
Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab (2010) 0.87
Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag (2008) 0.87
Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect (2007) 0.87
Local bone enhancement fuzzy clustering for segmentation of MR trabecular bone images. Med Phys (2010) 0.87
Phytonutrients for bone health during ageing. Br J Clin Pharmacol (2013) 0.86
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int (2006) 0.85
Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS). Osteoporos Int (2013) 0.85
Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int (2008) 0.85
Bisphosphonates and bone quality. Bonekey Rep (2014) 0.85
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int (2005) 0.83
Magnetic resonance imaging assessed cortical porosity is highly correlated with μCT porosity. Bone (2014) 0.83
RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res (2010) 0.83
Structural parameters of normal and osteoporotic human trabecular bone are affected differently by microCT image resolution. Osteoporos Int (2010) 0.82
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. Eur J Epidemiol (2009) 0.81
Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative hormone intervention trials. J Bone Miner Res (2008) 0.81
Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab (2016) 0.81
Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab (2007) 0.80
Quantifying mineralization using bone mineral density distribution in the mandible. J Craniofac Surg (2012) 0.80
Non-linear pattern formation in bone growth and architecture. Front Endocrinol (Lausanne) (2015) 0.78
Microarchitecture in focus. Osteoporos Int (2010) 0.78
Effect of high dietary sodium on bone turnover markers and urinary calcium excretion in Korean postmenopausal women with low bone mass. Eur J Clin Nutr (2015) 0.78
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2006) 0.77
Alendronate sodium in the management of osteoporosis. Ther Clin Risk Manag (2006) 0.77
QCT bone mineral density responses to 1 year of oral bisphosphonate after total knee replacement for knee osteoarthritis. Osteoporos Int (2012) 0.77
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? Osteoporos Int (2009) 0.77
Microarchitecture parameters describe bone structure and its strength better than BMD. ScientificWorldJournal (2012) 0.76
Mechanical competence of ovariectomy-induced compromised bone after single or combined treatment with high-frequency loading and bisphosphonates. Sci Rep (2015) 0.76
Osteopenia: a diagnostic and therapeutic challenge. Curr Osteoporos Rep (2011) 0.76
Biomechanical effects of simulated resorption cavities in cancellous bone across a wide range of bone volume fractions. J Bone Miner Res (2012) 0.76
Clinical cone beam computed tomography compared to high-resolution peripheral computed tomography in the assessment of distal radius bone. Osteoporos Int (2016) 0.76
Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents. Osteoporos Int (2007) 0.75
Letter to the editor. Bone (2004) 0.75
In vivo evaluation of bone microstructure in humans: Clinically useful? Bonekey Rep (2016) 0.75
Vertebral compression fractures during chemotherapy for childhood acute lymphoblastic leukemia: commentary on a report from the STeroid Associated Osteoporosis in the Pediatric Population (STOPP) research program. Transl Pediatr (2012) 0.75
Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women. Obstet Gynecol Sci (2013) 0.75
An NMR metabolomic study on the effect of alendronate in ovariectomized mice. PLoS One (2014) 0.75
Pharmacologic treatment to prevent fractures: from markers to patients. Osteoporos Int (2009) 0.75
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet (2010) 4.08
Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res (2003) 2.48
Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med (2010) 2.38
The perspective of the international osteoporosis foundation on the official positions of the international society for clinical densitometry. J Clin Densitom (2005) 2.14
Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res (2006) 2.04
Common variants in the region around Osterix are associated with bone mineral density and growth in childhood. Hum Mol Genet (2009) 1.99
Compliance with osteoporosis therapy is the weakest link. Lancet (2006) 1.84
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone (2006) 1.81
Fracture risk and height: an association partly accounted for by cortical porosity of relatively thinner cortices. J Bone Miner Res (2013) 1.62
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust (2002) 1.59
Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res (2008) 1.58
Differences in macro- and microarchitecture of the appendicular skeleton in young Chinese and white women. J Bone Miner Res (2009) 1.55
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int (2005) 1.51
Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res (2004) 1.50
The characteristics of fractures in Polish adolescents aged 16-20 years. Osteoporos Int (2005) 1.49
Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res (2004) 1.44
Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone (2012) 1.41
Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin (2004) 1.28
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res (2014) 1.21
Structural adaptations to bone loss in aging men and women. Bone (2005) 1.18
Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol (2009) 1.17
Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res (2010) 1.15
Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone (2005) 1.12
Epidemiology of hip and wrist fractures in Cameroon, Africa. Osteoporos Int (2003) 1.11
Rapid growth produces transient cortical weakness: a risk factor for metaphyseal fractures during puberty. J Bone Miner Res (2010) 1.06
A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromso Study. Eur J Endocrinol (2007) 1.05
Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res (2009) 1.04
Cortical bone: a challenging geography. J Bone Miner Res (2015) 1.02
An exercise in geometry. J Bone Miner Res (2002) 0.99
Construction of the femoral neck during growth determines its strength in old age. J Bone Miner Res (2007) 0.98
Circulating sex steroids, sex hormone-binding globulin, and longitudinal changes in forearm bone mineral density in postmenopausal women and men: the Tromsø study. Calcif Tissue Int (2007) 0.98
The structural and hormonal basis of sex differences in peak appendicular bone strength in rats. J Bone Miner Res (2003) 0.96
Structural and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians. Bone (2005) 0.93
Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab (2008) 0.93
Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women. J Bone Miner Res (2014) 0.93
Differences in the degree of bone tissue mineralization account for little of the differences in tissue elastic properties. Bone (2011) 0.93
The effect of acute exercise on undercarboxylated osteocalcin and insulin sensitivity in obese men. J Bone Miner Res (2014) 0.93
The fracture risk index and bone mineral density as predictors of vertebral structural failure. Osteoporos Int (2005) 0.93
New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone (2013) 0.92
Femoral neck fragility in women has its structural and biomechanical basis established by periosteal modeling during growth and endocortical remodeling during aging. Osteoporos Int (2003) 0.91
Osteoporosis and the global competition for health care resources. J Bone Miner Res (2004) 0.89
Seizures after alendronate. J R Soc Med (2002) 0.89
Trabecular bone of growth plate origin influences both trabecular and cortical morphology in adulthood. J Bone Miner Res (2011) 0.88
Familial resemblance and diversity in bone mass and strength in the population are established during the first year of postnatal life. J Bone Miner Res (2010) 0.87
Loss of regularity in the curvature of the thoracolumbar spine: a measure of structural failure. J Bone Miner Res (2004) 0.87
Bone's structural diversity in adult females is established before puberty. J Clin Endocrinol Metab (2009) 0.86
Skeletal growth and peak bone strength. Best Pract Res Clin Endocrinol Metab (2008) 0.85
Bone quality. Osteoporos Int (2003) 0.84
New mechanisms and targets in the treatment of bone fragility. Clin Sci (Lond) (2007) 0.84
Role of cortical bone in bone fragility. Curr Opin Rheumatol (2015) 0.84
DNA-binding-dependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females. J Endocrinol (2010) 0.84
Trabecular and cortical microstructure and fragility of the distal radius in women. J Bone Miner Res (2015) 0.83
Remodeling markers are associated with larger intracortical surface area but smaller trabecular surface area: a twin study. Bone (2011) 0.83
Depression in anorexia nervosa: a risk factor for osteoporosis. J Clin Endocrinol Metab (2005) 0.83
Third metacarpal condylar fatigue fractures in equine athletes occur within previously modelled subchondral bone. Bone (2010) 0.82
Genetic and environmental variances of bone microarchitecture and bone remodeling markers: a twin study. J Bone Miner Res (2015) 0.82
A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med (2004) 0.81
The age of puberty determines sexual dimorphism in bone structure: a male/female co-twin control study. J Clin Endocrinol Metab (2009) 0.81
Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate. J Bone Miner Res (2007) 0.80
Femoral neck shape and the spatial distribution of its mineral mass varies with its size: Clinical and biomechanical implications. Bone (2005) 0.79
The heterogeneity in femoral neck structure and strength. J Bone Miner Res (2013) 0.78
Inappropriate prescribing for osteoporosis. Med J Aust (2009) 0.78
Diet and exercise during growth have site-specific skeletal effects: a co-twin control study. Osteoporos Int (2005) 0.77
The varying distribution of intra- and inter-vertebral height ratios determines the prevalence of vertebral fractures. Bone (2004) 0.77
Architecture of cortical bone determines in part its remodelling and structural decay. Bone (2013) 0.76
The shifting trajectory of growth in femur length during gestation. J Bone Miner Res (2010) 0.76
Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study. Osteoporos Int (2004) 0.76
Alendronate and vertebral fracture risk. Mayo Clin Proc (2005) 0.76
Body segment lengths and arm span in healthy men and women and patients with vertebral fractures. Osteoporos Int (2003) 0.76
A Single Dose of Prednisolone as a Modulator of Undercarboxylated Osteocalcin and Insulin Sensitivity Post-Exercise in Healthy Young Men: A Study Protocol. JMIR Res Protoc (2016) 0.75
Pierre D Delmas. J Bone Miner Res (2008) 0.75
Hypocalcemia induced by raloxifene. Curr Drug Saf (2012) 0.75